US EditionImmunogenicity, Pharmaceutics, and Properties of Recombinant A. flavus Uricase Modified by CA/EDA Carbon Dots
Summary by researchsquare.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Immunogenicity, Pharmaceutics, and Properties of Recombinant A. flavus Uricase Modified by CA/EDA Carbon Dots
Background Clinically, patients with gout are often treated with uricase (Uox)-based drugs. While these medications are effective, many patients suffer from immune rejection associated with their use. To reduce Uox’s immunogenicity, it was modified with carbon dots synthesized f...
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage